Enoxacin as one day oral treatment of men with anal or pharyngeal gonorrhoea

M BAHTIAR,* P L SAMARASINGHE†

From the Departments of *Medical Microbiology and †Genitourinary Medicine, Westminster Hospital, London

SUMMARY The efficacy of two regimens of oral enoxacin (400 mg as a single dose or two 200 mg doses 12 hours apart) to treat anal and pharyngeal gonorrhoea was compared. Fifty men with confirmed gonorrhoea (40 with anal, six with pharyngeal, and four with both) were treated and assessed three to five and seven to 14 days after treatment. Of 44 evaluable patients who attended the first follow up, including those who were infected with penicillinase producing Neisseria gonorrhoeae (PPNG), all were cured. No haematological or biochemical abnormality associated with enoxacin was observed. Nine patients reported minor adverse effects during the trial period, only one of which was considered probably related to the treatment. Both regimens of 400 mg enoxacin were effective in treating anal and pharyngeal gonorrhoea.

The recent rise in resistance of clinical isolates of Neisseria gonorrhoeae to antibiotics has led clinicians to search for alternative antibacterial agents to treat this common venereal infection. New quinolone derivatives with their high in vitro activity and oral administration are potentially useful, and successful treatment of urethral gonorrhoea has been reported using these agents.12

Enoxacin, a fluorinated derivative of pipemidic acid, is a new oral quinolone preparation that has been shown to have in vitro activity against Staphylococcus aureus and a wide range of aerobic Gram negative organisms including N gonorrhoeae.14

Enoxacin has been reported to have a larger volume of distribution and greater tissue concentrations than other newly developed quinolones such as ciprofloxacin and norfloxacin,15 and has been successfully used to treat urethral gonorrhoea as a single 600 mg oral dose.7 In this study we compared the efficacy of two dosage regimens of enoxacin with a total dose of 400 mg in treating pharyngeal and rectal gonorrhoea.

Patients, materials, and methods

We studied 50 men attending the genitourinary medicine outpatient department at the Westminster Hospital to compare two dosage regimens of enoxacin, a single 400 mg dose or two 200 mg doses 12 hours apart. The study was approved by the hospital Ethics Committee. Patients aged between 18 and 65 with anal or pharyngeal gonococcal infections, or both, were eligible for inclusion. Patients with any renal or hepatic impairment, disseminated gonorrhoea or syphilis, or a known allergy to quinolone derivatives, or who had previously been treated with enoxacin were excluded from the study. Of the 50 men (mean age of 29±9 (range 20–54) years, 48 were homosexual, one was bisexual, and one heterosexual. All gave fully informed consent to taking part in this study. Table 1 gives the characteristics of the patients, which were comparable for the two treatment groups. Clinical diagnosis was based on the presence of rectal discharge, anorectal pain or itching, and sore throat; these symptoms were assessed as absent, mild, moderate, or severe. Initial diagnosis was further suggested in some patients by evidence of intracellular Gram negative diplococci on Gram stained anal or pharyngeal smears, and was confirmed by the isolation of N gonorrhoeae on selective media. Table 2 gives

Table 1 Characteristics of 50 men with gonorrhoea treated with enoxacin 400 mg as one dose or in two equal doses 12 hours apart

<table>
<thead>
<tr>
<th></th>
<th>Single dose (n = 25)</th>
<th>Two doses (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (range) age (years)</td>
<td>27 (19–54)</td>
<td>32 (20–46)</td>
</tr>
<tr>
<td>No HIV antibody positive</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>No homosexual</td>
<td>25</td>
<td>23</td>
</tr>
<tr>
<td>No heterosexual</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>No bisexual</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

Accepted for publication 12 April 1988
diagnoses and symptoms; 40 patients had anal gonorrhoea (16 of whom were symptomless), six had pharyngeal gonorrhoea (three of whom were symptomless), and four had both anal and pharyngeal gonorrhoea, (two of whom were symptomless).

In a double blind, randomised, comparative trial we treated 25 men with 400 mg enoxacin as a single dose, and 25 with two doses of 200 mg enoxacin 12 hours apart. Blinding was achieved using identical placebo capsules, one given with each 200 mg dose of enoxacin to the men receiving two doses and two given 12 hours after the 400 mg dose to the men receiving one dose. Patients were asked to refrain from sexual activity during the whole study period. Follow up examinations with clinical evaluation and direct microscopy, were made at three to five and seven to 10 days after treatment. Cultures of material from the anus or pharynx, or both, were also carried out at each visit. Patients were questioned regarding their sexual activity since treatment. Blood was taken before and after treatment for haematological and biochemical investigations.

Using an agar doubling dilution method, we measured the minimum inhibitory concentrations (MICs) of enoxacin, ampicillin, benzylpenicillin, piperacillin, and cefuroxime against each strain of *N. gonorrhoeae*. Isolates were also tested for LB lactamase production.

**Results**

Of the 50 men, 44 were clinically symptom free and bacteriologically cured when examined three to five days after treatment (table 3). One had had sexual contact with his original partner after treatment, and a second isolate of *N. gonorrhoeae* was shown to have the same sensitivity pattern as the original strain. Five men were lost to follow up at that stage. Thus both regimens were completely successful in evaluable patients. The MICs of enoxacin against all the gonococci isolated in this study, including three LB lactamase producers, were very low (MIC<sub>90</sub> = 0.025–0.25 mg/l, range 0.025–0.25 mg/l). The MICs of other antibiotics were considerably more variable (ampicillin MIC<sub>90</sub> = 1.0 mg/l, range 0.06–16 mg/l; benzylpenicillin MIC<sub>90</sub> = 0.025–0.25 mg/l, range 0.03–16 mg/l; cefuroxime MIC<sub>90</sub> = 1.0 mg/l, range 0.06–2.0 mg/l; and piperacillin MIC<sub>90</sub> = 1.0 mg/l, range 0.03–16 mg/l).

No major clinical adverse reactions occurred in any of the patients (including 11 with antibody to HIV), and haematological and biochemical markers were not affected. Nine patients, five who received a single dose and four who received two doses, complained of mild adverse events ranging from a slight headache to light diarrhoea, but these events were not always related to the treatment. A second follow up appointment seven to 10 days after treatment showed a continuation of cure in all the men examined, though 17 men failed to attend this appointment.

**Discussion**

The occurrence of resistance to antibiotics has forced clinicians to use antibiotics other than those previously used to treat rectal or pharyngeal gonorrhoea. LB lactamase resistant parenteral cephalosporins can be useful against resistant strains, although mechanisms of resistance other than the production of LB lactamase have been described in the United States of America. Furthermore, Hook and Holmes reported in 1985 that gonococci isolated from homosexual men with rectal gonorrhoea carry “mtr” genes that confer a degree of resistance to several antibiotics.

The quinolone derivatives have previously been successfully used orally to treat gonorrhoea. In our
study all patients were cured of anorectal and pharyngeal gonorrhoea using 400 mg enoxacin. The single patient withdrawn from the study gave evidence of reinfection, rather than lack of response to treatment. The gonococci isolated after reinfection from this patient had the same sensitivity to enoxacin as the original isolate, in contrast to the finding of Wagenvoort et al in 1986, who reported development of resistance to enoxacin in gonococci during treatment. No serious side effects attributed to enoxacin were observed in this study.

In the light of these results we think that 400 mg enoxacin given orally as a single or divided dose is an effective treatment for rectal and pharyngeal gonorrhoea.

References